CD38 and hepatocellular carcinoma: In the same way, an elevation of the frequency of CD19+CD24+CD38− primarily memory B cell subset (from CD19+ B cells) was observed in the CHC-N, CHC-LC, and CHC-HCC patients compared with the healthy controls (mean, 29.4 ± 3, 21.5 ± 3, 29 ± 3 vs. 14.6 ± 3, p = 0.001, p = 0.1, p = 0.002, respectively), but with no significant difference between CHC-LC patients and control group.